NOVN.SW

$121.44

Market ClosedAs of Mar 16, 4:30 PM UTC

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$121.44
Potential Upside
13%
Whystock Fair Value$137.24
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$231.73B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.38
Beta
Defensive asset. Lower volatility than the S&P 500.
0.50
Div Yield
Strong income play. Yield provides a meaningful total return floor.
305.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
30.81%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.82

Recent News

MT Newswires
Mar 16, 2026

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Moby
Mar 16, 2026

Julius Baer’s $30 Million Pay Package Shows the Price of a Banking Reset

The Swiss private bank paid its new boss more than UBS chief Sergio Ermotti, highlighting how costly it can be to rebuild credibility after a major scandal

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Mar 16, 2026

FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents

Novartis wins FDA nod to expand Cosentyx use to teens with hidradenitis suppurativa, making it the only IL-17A inhibitor for this group.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 13, 2026

Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?

Gilead plans a $7.8B Arcellx acquisition as cell therapy sales decline, seeking full control of anito-cel to strengthen its oncology pipeline.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 13, 2026

Assessing Novartis (SWX:NOVN) Valuation After Recent Mixed Share Price Performance

Novartis (SWX:NOVN) has drawn fresh attention after recent share price moves, with the stock showing mixed short term returns but a stronger result over the past 3 months and year. See our latest analysis for Novartis. Recent trading has been softer, with a 7 day share price return of 3.19% and a 30 day share price return of a 0.13% decline. However, the 90 day share price return of 14.54% and 1 year total shareholder return of 28.46% indicate that momentum has been building over a longer...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.